Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

By sjmartinez • June 9, 2024

Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. J Thorac Oncol. 2024 Jun;19(6):928-940. doi: 10.1016/j.jtho.2024.01.012. Epub 2024 Jan 24. PMID: 38278303.

Tags: Adverse events, Cedars Sinai DoM, chemotherapy, durvalumab, EGFR, Hematology/Oncology, Non–small cell lung cancer, Osimertinib, Publications, targeted therapy

Coronary Artery Calcium (CAC) Imaging as a Diagnostic Test: Insurance Coverage Implications

Naghavi M, Wong ND, McConnell MV, Maron DJ, Nasir K, Henschke CI, Yankelevitz DF, A Fayad Z, Vliegenthart R, Williams KA Sr, Mehran R, Budoff[...]

Clinical features, management, and outcomes of right heart thrombi: a retrospective cohort study

Fritzmann E, Yuen AD, Chang S, Yaqoob M, Kinninger A, Chung J, Vintch JRE, Matusov Y. Clinical features, management, and outcomes of right heart thrombi:[...]

Stress Cardiac Magnetic Resonance Ischemia Burden and Cardiovascular Events: Post-Hoc Analysis From the ISCHEMIA Trial

Kwong RY, Heydari B, Abbasi S, Mongeon FP, Marcotte F, Friedrich M, Shaw LJ, Xu Y, Anthopolos R, Bekeredjian R, Monti L, Selvanayagam J, Lesiak[...]